Latest Period
Q2 2026
Security Snapshot
GSK plc - Ordinary Shares and American Depositary Shares (GSK) Institutional Ownership
CUSIP: 37733W204
13F Institutional Holders and Ownership History from Q1 2016 to Q2 2026
Institutions Reporting
1,032
Shares (Excl. Options)
346,523,277
Price
$52.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares and American Depositary Shares
- Symbol
- GSK on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 346,523,277
- Total 13F value
- $18,163,928,962
- Portfolio coverage rank
- 0.02%
- Share change
- -27,484,034
- Value change
- -$1,461,109,686
- Number of holders
- 1,032
- Shares outstanding
- 4,029,280,651
- SEC-reported price per share
- $51.35
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GSK - GSK plc - Ordinary Shares and American Depositary Shares is tracked under CUSIP 37733W204.
- 1032 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1,028 to 1,032 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $20,653,024,789 to $18,163,928,962.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1032 institutions filings for Q2 2026.
Security key
37733W204
Latest holder period
Q2 2026
13F holders
1,032
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
GSK full holder history
GSK plc SEC filings
GSK plc company facts
GSK plc 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 37733W204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
GSK
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| DODGE & COX | 4.3% | $9,090,903,298 | 173,259,068 | Dodge & Cox | 30 Jun 2026 |
As of 30 Jun 2026, 1,032 institutional investors reported holding 346,523,277 shares of GSK plc - Ordinary Shares and American Depositary Shares (GSK). This represents 8.6% of the company’s total 4,029,280,651 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q2 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 346,523,277 | $18,163,928,962 | -$1,461,109,686 | $52.42 | 1,032 |
| 2026 Q1 | 374,189,642 | $20,653,024,789 | -$1,226,574,037 | $55.19 | 1,028 |
| 2025 Q4 | 397,707,646 | $19,505,789,840 | +$560,994,497 | $49.04 | 990 |
| 2025 Q3 | 385,810,445 | $16,653,456,346 | +$149,628,861 | $43.16 | 883 |
| 2025 Q2 | 377,323,511 | $14,492,600,704 | +$691,641,935 | $38.40 | 873 |
| 2025 Q1 | 365,061,086 | $14,138,125,686 | +$1,006,993,911 | $38.74 | 839 |
| 2024 Q4 | 340,917,752 | $11,541,588,389 | +$1,180,300,325 | $33.82 | 833 |
| 2024 Q3 | 302,968,498 | $12,377,977,607 | -$140,106,119 | $40.88 | 883 |
| 2024 Q2 | 309,126,756 | $11,909,339,872 | -$23,346,819 | $38.50 | 869 |
| 2024 Q1 | 308,583,941 | $13,222,947,461 | +$833,173,631 | $42.87 | 891 |
| 2023 Q4 | 289,484,844 | $10,732,131,887 | +$174,194,109 | $37.06 | 882 |
| 2023 Q3 | 284,245,298 | $10,307,406,122 | +$264,432,361 | $36.25 | 835 |
| 2023 Q2 | 276,495,626 | $9,857,311,052 | +$194,467,459 | $35.64 | 814 |
| 2023 Q1 | 269,710,676 | $9,600,329,935 | -$208,079,525 | $35.58 | 792 |
| 2022 Q4 | 276,203,256 | $9,708,565,984 | +$516,369,806 | $35.14 | 788 |
| 2022 Q3 | 264,324,002 | $7,785,299,734 | +$7,652,922,694 | $29.43 | 697 |
| 2022 Q2 | 4,250,301 | $185,367,037 | +$183,087,502 | $43.53 | 67 |
| 2022 Q1 | 52,302 | $2,281,067 | -$356,058 | $43.56 | 7 |
| 2021 Q4 | 60,336 | $2,667,168 | -$139,973 | $44.10 | 7 |
| 2021 Q3 | 17,405 | $671,931 | +$7,790 | $38.21 | 6 |
| 2021 Q2 | 17,188 | $691,875 | -$30,222 | $39.82 | 6 |
| 2021 Q1 | 17,949 | $649,577 | +$393,265 | $35.69 | 6 |
| 2020 Q4 | 7,178 | $264,151 | -$29,072 | $36.80 | 4 |
| 2020 Q3 | 7,968 | $299,261 | +$325 | $37.64 | 4 |
| 2020 Q2 | 7,971 | $325,296 | -$17,284 | $40.79 | 3 |